Can-Fite BioPharma Ltd. (CANF)

Market Cap	14.75M
Revenue (ttm)	667,000
Net Income (ttm)	-7.37M
Shares Out	1.67B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,514
Open	2.050
Previous Close	2.030
Day's Range	1.900 - 2.090
52-Week Range	1.830 - 4.690
Beta	0.57
Analysts	Strong Buy
Price Target	14.00 (+596.52%)
Earnings Date	Nov 26, 2024

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 8
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CANF
• Website: https://www.canfite.com

Financial Performance

In 2023, Can-Fite BioPharma's revenue was $743,000, a decrease of -8.27% compared to the previous year's $810,000. Losses were -$7.63 million, -24.96% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CANF stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 596.52% from the latest price.

Price Target

$14.0

(596.52% upside)

Analyst Consensus: Strong Buy